JPH0521892B2 - - Google Patents
Info
- Publication number
- JPH0521892B2 JPH0521892B2 JP59070736A JP7073684A JPH0521892B2 JP H0521892 B2 JPH0521892 B2 JP H0521892B2 JP 59070736 A JP59070736 A JP 59070736A JP 7073684 A JP7073684 A JP 7073684A JP H0521892 B2 JPH0521892 B2 JP H0521892B2
- Authority
- JP
- Japan
- Prior art keywords
- dipyridamole
- acid
- tablet
- weight
- starch glycolate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960002768 dipyridamole Drugs 0.000 claims abstract description 63
- 239000002253 acid Substances 0.000 claims abstract description 47
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 8
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000013270 controlled release Methods 0.000 claims abstract description 6
- 239000007935 oral tablet Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims description 53
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 28
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 22
- 239000001530 fumaric acid Substances 0.000 claims description 21
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 15
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 15
- 239000008109 sodium starch glycolate Substances 0.000 claims description 15
- 239000007884 disintegrant Substances 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 229940096978 oral tablet Drugs 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 3
- 229960005168 croscarmellose Drugs 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 229940071117 starch glycolate Drugs 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 abstract description 24
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000011872 intimate mixture Substances 0.000 abstract description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000000034 method Methods 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002245 particle Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical class NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960003403 betaine hydrochloride Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical class [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- -1 hydrochloric Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical class [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48328583A | 1983-04-08 | 1983-04-08 | |
| US483285 | 1983-04-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6034906A JPS6034906A (ja) | 1985-02-22 |
| JPH0521892B2 true JPH0521892B2 (enExample) | 1993-03-25 |
Family
ID=23919470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59070736A Granted JPS6034906A (ja) | 1983-04-08 | 1984-04-09 | ジピリダモール経口錠剤 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0121901B1 (enExample) |
| JP (1) | JPS6034906A (enExample) |
| KR (1) | KR880002139B1 (enExample) |
| AT (1) | ATE32980T1 (enExample) |
| AU (1) | AU570446B2 (enExample) |
| CA (1) | CA1219216A (enExample) |
| DD (1) | DD222496A5 (enExample) |
| DE (1) | DE3469848D1 (enExample) |
| DK (1) | DK166259C (enExample) |
| ES (1) | ES8601687A1 (enExample) |
| FI (1) | FI82604C (enExample) |
| GR (1) | GR81907B (enExample) |
| HU (1) | HU191542B (enExample) |
| IE (1) | IE57220B1 (enExample) |
| IL (1) | IL71458A (enExample) |
| NO (1) | NO164958C (enExample) |
| NZ (1) | NZ207768A (enExample) |
| PH (1) | PH21585A (enExample) |
| PT (1) | PT78380B (enExample) |
| ZA (1) | ZA842562B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| JPH0776172B2 (ja) * | 1986-04-16 | 1995-08-16 | 藤沢薬品工業株式会社 | マトリツクス錠 |
| JP2535141B2 (ja) * | 1995-01-17 | 1996-09-18 | 中外製薬株式会社 | フマル酸含有徐放性製剤 |
| DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| BG860Y1 (bg) * | 2004-09-17 | 2007-02-28 | "Софарма" Ад | Лекарствена форма на дипиридамол |
| EP1919460A2 (en) * | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| CA2671470C (en) | 2006-12-13 | 2012-05-01 | F. Hoffmann-La Roche Ag | Powder formulation for valganciclovir |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| DD146547A5 (de) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| JPS5839618A (ja) * | 1981-09-04 | 1983-03-08 | Chugai Pharmaceut Co Ltd | 持続性積層錠剤 |
-
1984
- 1984-04-03 KR KR1019840001834A patent/KR880002139B1/ko not_active Expired
- 1984-04-03 HU HU841328A patent/HU191542B/hu not_active IP Right Cessation
- 1984-04-04 AT AT84103698T patent/ATE32980T1/de not_active IP Right Cessation
- 1984-04-04 EP EP84103698A patent/EP0121901B1/en not_active Expired
- 1984-04-04 DE DE8484103698T patent/DE3469848D1/de not_active Expired
- 1984-04-05 GR GR74334A patent/GR81907B/el unknown
- 1984-04-05 ZA ZA842562A patent/ZA842562B/xx unknown
- 1984-04-06 AU AU26609/84A patent/AU570446B2/en not_active Ceased
- 1984-04-06 DD DD84261735A patent/DD222496A5/de not_active IP Right Cessation
- 1984-04-06 DK DK181084A patent/DK166259C/da not_active IP Right Cessation
- 1984-04-06 FI FI841369A patent/FI82604C/fi not_active IP Right Cessation
- 1984-04-06 NZ NZ207768A patent/NZ207768A/en unknown
- 1984-04-06 PT PT78380A patent/PT78380B/pt unknown
- 1984-04-06 NO NO841372A patent/NO164958C/no not_active IP Right Cessation
- 1984-04-06 IE IE856/84A patent/IE57220B1/en not_active IP Right Cessation
- 1984-04-06 CA CA000451489A patent/CA1219216A/en not_active Expired
- 1984-04-06 ES ES531346A patent/ES8601687A1/es not_active Expired
- 1984-04-06 PH PH30512A patent/PH21585A/en unknown
- 1984-04-06 IL IL71458A patent/IL71458A/xx not_active IP Right Cessation
- 1984-04-09 JP JP59070736A patent/JPS6034906A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DK166259B (da) | 1993-03-29 |
| PT78380A (en) | 1984-05-01 |
| DK181084A (da) | 1984-10-09 |
| ES531346A0 (es) | 1985-11-01 |
| IE57220B1 (en) | 1992-06-03 |
| GR81907B (enExample) | 1984-12-12 |
| EP0121901B1 (en) | 1988-03-16 |
| AU2660984A (en) | 1984-10-11 |
| NO841372L (no) | 1984-10-09 |
| HUT34345A (en) | 1985-03-28 |
| JPS6034906A (ja) | 1985-02-22 |
| KR840008588A (ko) | 1984-12-17 |
| PH21585A (en) | 1987-12-11 |
| IE840856L (en) | 1984-10-08 |
| DK181084D0 (da) | 1984-04-06 |
| FI82604B (fi) | 1990-12-31 |
| DK166259C (da) | 1993-08-23 |
| NO164958B (no) | 1990-08-27 |
| EP0121901A1 (en) | 1984-10-17 |
| PT78380B (en) | 1986-08-14 |
| CA1219216A (en) | 1987-03-17 |
| IL71458A0 (en) | 1984-07-31 |
| ATE32980T1 (de) | 1988-04-15 |
| AU570446B2 (en) | 1988-03-17 |
| ES8601687A1 (es) | 1985-11-01 |
| DE3469848D1 (en) | 1988-04-21 |
| FI82604C (fi) | 1991-04-10 |
| NO164958C (no) | 1990-12-05 |
| KR880002139B1 (ko) | 1988-10-17 |
| NZ207768A (en) | 1987-02-20 |
| ZA842562B (en) | 1985-12-24 |
| IL71458A (en) | 1987-09-16 |
| HU191542B (en) | 1987-03-30 |
| DD222496A5 (de) | 1985-05-22 |
| FI841369L (fi) | 1984-10-09 |
| FI841369A0 (fi) | 1984-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
| JP4920798B2 (ja) | ２種以上の粒子を含有する口腔内速崩壊錠 | |
| ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
| KR0163056B1 (ko) | 피모벤단의 경구용 약제학적 투여형 | |
| CN1863517B (zh) | 快速崩解制剂 | |
| CA2182004C (en) | Film coated tablet of paracetamol and domperidone | |
| CN101237858B (zh) | 胃滞留制剂及其制备方法 | |
| IE53543B1 (en) | New oral dipyridamole preparations | |
| EP0221732A2 (en) | Sustained release tablets | |
| JPWO2005055989A1 (ja) | 薬物含有粒子および該粒子を含む固形製剤 | |
| JP5122984B2 (ja) | 改良された薬物動態学的特性を有する製剤 | |
| WO2007108010A2 (en) | Taste masked pharmaceutical composition for oral solid dosage form and process for preparing the same using magnesium aluminium silicate | |
| JP5417662B2 (ja) | ネビラピンの徐放性製剤 | |
| JPH0521892B2 (enExample) | ||
| JP3836893B2 (ja) | ポリカルボフィルカルシウム含有製剤 | |
| RU2359660C2 (ru) | Фармацевтическая композиция, содержащая производное пиримидин-а-она, покрытая кишечнорастворимым полимером | |
| JP2003300872A (ja) | 被覆固形催眠製剤 | |
| JP2008081448A (ja) | 酒石酸ゾルピデムの苦味マスキング速放性粒子 | |
| JPH04230626A (ja) | 改良されたゲムフィブロジル組成物 | |
| JPWO2003075918A1 (ja) | 塩酸ピルジカイニド含有錠剤（湿式） | |
| JP2007015966A (ja) | 口腔内崩壊錠 |